Zentalis Pharmaceuticals Llc Stock Current Liabilities
| ZNTL Stock | USD 3.23 0.05 1.57% |
Zentalis Pharmaceuticals Llc fundamentals help investors to digest information that contributes to Zentalis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zentalis Stock. The fundamental analysis module provides a way to measure Zentalis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zentalis Pharmaceuticals stock.
The value of Total Current Liabilities is estimated to slide to about 40.3 M. The value of Non Current Liabilities Total is expected to slide to about 27.5 M. Zentalis | Current Liabilities |
Zentalis Pharmaceuticals Llc Company Current Liabilities Analysis
Zentalis Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Zentalis Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Zentalis Pharmaceuticals is extremely important. It helps to project a fair market value of Zentalis Stock properly, considering its historical fundamentals such as Current Liabilities. Since Zentalis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zentalis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zentalis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Zentalis Current Liabilities Historical Pattern
Today, most investors in Zentalis Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Zentalis Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Zentalis Pharmaceuticals current liabilities as a starting point in their analysis.
Zentalis Pharmaceuticals Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Zentalis Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Zentalis Pharmaceuticals Llc has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Zentalis Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zentalis Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics of similar companies.Zentalis Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Zentalis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Zentalis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Zentalis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Zentalis Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (5.16) % | ||||
| Current Valuation | (120.61 M) | ||||
| Shares Outstanding | 71.27 M | ||||
| Shares Owned By Insiders | 3.46 % | ||||
| Shares Owned By Institutions | 98.18 % | ||||
| Number Of Shares Shorted | 7.05 M | ||||
| Price To Book | 0.64 X | ||||
| Price To Sales | 5.68 X | ||||
| EBITDA | (275.5 M) | ||||
| Net Income | (292.19 M) | ||||
| Cash And Equivalents | 455.22 M | ||||
| Cash Per Share | 7.99 X | ||||
| Total Debt | 43.15 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 9.61 X | ||||
| Book Value Per Share | 4.98 X | ||||
| Cash Flow From Operations | (207.82 M) | ||||
| Short Ratio | 5.49 X | ||||
| Earnings Per Share | (2.50) X | ||||
| Target Price | 9.5 | ||||
| Number Of Employees | 124 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 230.19 M | ||||
| Total Asset | 551.69 M | ||||
| Retained Earnings | (888.56 M) | ||||
| Working Capital | 427.35 M | ||||
| Net Asset | 551.69 M |
About Zentalis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zentalis Pharmaceuticals Llc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis Pharmaceuticals Llc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Zentalis Pharmaceuticals Piotroski F Score and Zentalis Pharmaceuticals Altman Z Score analysis. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.50) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.